Monday, October 28,
2024, at 8:30 a.m. EDT
DUBLIN and CHICAGO, Oct. 28,
2024 /PRNewswire/ --
|
WHO:
|
Iterum Therapeutics plc
(Nasdaq: ITRM) is focused on delivering
differentiated anti-infectives aimed at combatting the global
crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by
serious and life-threatening diseases around the world.
|
|
WHAT:
|
Conference call to
discuss U.S. Food and Drug Administration (FDA) approval of
Iterum's ORLYNVAH™ (Oral Sulopenem) for the treatment of
uncomplicated
urinary tract infections (uUTIs).
Speakers include: Corey Fishman (CEO) and Steve Aronin (Senior
Vice
President and Head of Clinical Development
|
|
|
|
WHY:
|
ORLYNVAH™ (sulopenem
etzadroxil and probenecid) is the first oral penem
approved for use in the U.S. and the first FDA-approved product for
Iterum.
ORLYNVAH™ is approved for the treatment of uUTIs caused by the
designated
microorganisms Escherichia coli, Klebsiella
pneumoniae or Proteus mirabilis in
adult women who have limited or no alternative oral antibacterial
treatment
options. It is only the second FDA-approved treatment for uUTIs in
the past two
decades.
For more details, view the press release issued Friday
here.
|
|
|
|
WHEN:
|
Monday, October 28,
2024
8:30 a.m. Eastern Daylight Time
|
|
|
|
Dial-in
information:
United States: +1 833-470-1428 | International: +1 404-975-4839
Access code: 936149
|
|
|
|
The conference call
replay will be available in the Events & Presentations
page of Iterum's website following the call.
|
About Iterum Therapeutics plc
Iterum Therapeutics
plc is focused on delivering differentiated anti-infectives aimed
at combatting the global crisis of multi-drug resistant pathogens
to significantly improve the lives of people affected by serious
and life-threatening diseases around the world. Iterum is advancing
the development of its first compound, sulopenem, a novel penem
anti-infective compound, with an oral formulation and IV
formulation. Sulopenem has demonstrated potent in vitro activity
against a wide variety of gram-negative, gram-positive and
anaerobic bacteria resistant to other antibiotics. Iterum has
received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the
treatment of uncomplicated urinary tract infections caused by the
designated microorganisms Escherichia coli, Klebsiella
pneumoniae, or Proteus mirabilis in adult women with
limited or no alternative oral antibacterial treatment options by
the U.S. Food and Drug Administration and has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications. For
more information, please visit www.iterumtx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/iterum-therapeutics-to-host-morning-conference-call-on-us-fda-approval-of-orlynvah-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections-302288057.html
SOURCE Iterum Therapeutics plc
